Prelude Therapeutics Inc 8-K

What Happened

• On April 20, 2026, Prelude Therapeutics (PRLD) filed an 8‑K and issued a press release reporting new preclinical data for its lead candidate PRT13722, presented at the AACR Annual Meeting 2026. The company describes PRT13722 as a first‑in‑class, orally bioavailable, potent and selective KAT6A degrader. Prelude attached the press release (Exhibit 99.1) and an investor presentation deck (Exhibit 99.2) to the filing; the materials are furnished, not filed.

Key Details

• Presentation date and venue: AACR Annual Meeting, April 20, 2026.
• Mechanism: PRT13722 degrades KAT6A, which Prelude says produces broader pathway disruption than dual KAT6A/B inhibitors.
• Preclinical efficacy/safety: Durable complete tumor regressions observed as monotherapy in HR+/HER2- xenograft models (ET‑sensitive and ET‑experienced); showed synergy with endocrine therapy, CDK4/6 inhibitors, and PI3Kα inhibitors; improved preclinical hematologic safety versus prifetrastat.
• Development timeline: IND filing is on track for mid‑2026; pending IND clearance, Prelude anticipates starting a Phase 1 trial in the second half of 2026.

Why It Matters

• For investors, the filing highlights near‑term clinical milestones — an IND targeted for mid‑2026 and a potential Phase 1 start in H2 2026 — which are clear catalysts if achieved. The preclinical claims (strong monotherapy regressions, combination synergy, and a better hematologic safety profile) suggest PRT13722 could differentiate from existing approaches in HR+ breast cancer, but these are preclinical results; clinical studies will be needed to confirm safety and efficacy. The furnished press release and investor deck provide additional detail but are not “filed” for Exchange Act Section 18 purposes.